ViraxClear Signs Letter of Intent and Secures Purchase Order for Infrared Thermometers to North Africa
May 22 2020 - 2:00AM
Global Care Capital Corp. (CSE:
HLTH, FRANKFURT:
L6V1) (the
“
Company” or “
Global Care”) a
global investment company which engages in early stage investment
opportunities in private and public companies, is pleased to
announce that its portfolio company, ViraxClear, through its joint
venture Shanghai Biotechnology Devices Ltd.
(“
SBD”) has on May 20th, 2020, finalized a Letter
Of Intent (
LOI) with Phyto Pharma Ltd
(“
Phyto”), for the supply of 5,000 FDA Registered
and CE marked infrared thermometer units
(“
Thermometers”) for sale in North Africa, with a
Purchase Order signed for the value of US$ 125,000 for the 5,000
units.
James Foster, CEO of ViraxClear, states that,
“The sudden surge in numbers of novel coronavirus (COVID-19) cases
has caused nations across the globe to take steps to stop the
spread. Ever since the outbreak of the deadly disease, there has
been a need to routinely check temperatures. The temperature in
such cases is not checked using a mercury thermometer. To do this,
offices, airports, malls and hotels are using forehead
thermometers, also known as infrared thermometers. These
thermometers check the temperature by sensing the infrared energy
radiated by the body and are used to detect body temperature in
case of fever, one of the symptoms of coronavirus.”
“Securing FDA Registered and CE marked product
from a reputable manufacturer represents a significant opportunity
for ViraxClear and its distribution partners.”
LOI for Thermometers
ViraxClear has signed an LOI and purchase order
to distribute 5,000 infrared thermometers for sale to existing
Morocco based distribution partner Phyto for the region of North
Africa. An initial purchase order for 5,000 units has been signed,
with a value of US$125,000, which will be fulfilled in the coming
days. Phyto will be responsible for funding the shipping costs of
the thermometers. This represents the first sale of a new product
for ViraxClear, which primarily focuses on COVID-19 Antibody Test
Kits. Accessing the North African market is an important first step
in the roll out of infrared thermometers and other medical
devices.
Supply Agreement between SBD and Venus
ViraxClear has secured supply of the infrared
thermometers through Hong Kong based Venus Health Consulting
Limited (“Venus”) for the Guofengtai brand of
thermometers. Guofengtai is manufactured by China based Jiangxi
GuoFeng Medical Equipment Co. Ltd (“Jiangxi”).
The thermometers do not require contact with a
person and can swiftly measure temperature from 1cm-5cm from the
forehead. These are particularly useful for use in public places
like a hotel, airport, factory or office and with demand increasing
as people begin to return to their normal lives and places of work.
These are battery-operated, handy and easy to use thermometers,
which do not require any trained technicians. Whilst they are by no
means definitively accurate in the detection of COVID-19, they are
widely being used across the world to detect potential symptomatic
COVID-19 carriers.
The infrared thermometers are also an important
component of the ViraxClear Employee Protection Equipment (EPE)
Kits that it planning to launch next month: A scientifically
curated kit of key protective equipment, which will be crucial in
creating conditions for an acceptable level of safety in the
workplace.
About ViraxClear
ViraxClear focuses on commercializing novel
products that address significant healthcare needs with a
specific target on the novel coronavirus (COVID-19). The
company’s main focus is marketing its ViraxClear Rapid IgM-IgG
Combined Antibody Test. The ViraxClear Rapid IgM-IgG Combined
Antibody Test for COVID-19 is a lateral flow immunoassay used to
qualitatively detect both early and late marker IgG/IgM
antibodies.
About Global Care
Global Care Capital is a global investment
company which specializes in providing early stage financing to
private and public companies. The Company engages in new, early
stage investment opportunities in previously underdeveloped assets
and obtaining positions in early stage investment opportunities
that adequately reflect the risk profile.
GLOBAL CARE CAPITAL CORP.:
Company Contact:
Alex Somjen, President & CEO
asomjen@globalcarecapital.com
Neither the CSE nor its regulation
services provider accepts responsibility for the adequacy or
accuracy of this release.
Forward-Looking Information: This news release
includes certain statements that may be deemed “forward-looking
statements”. The use of any of the words “anticipate”, “continue”,
“estimate”, “expect”, “may”, “will”, “would”, “project”, “should”,
“believe” and similar expressions are intended to identify
forward-looking statements. Although the Company believes that the
expectations and assumptions on which the forward-looking
statements are based are reasonable, undue reliance should not be
placed on the forward-looking statements because the Company can
give no assurance that they will prove to be correct. Since
forward-looking statements address future events and conditions, by
their very nature they involve inherent risks and uncertainties.
These statements speak only as of the date of this News Release.
Actual results could differ materially from those currently
anticipated due to a number of factors and risks including various
risk factors discussed in the Company’s disclosure documents which
can be found under the Company’s profile on www.sedar.com
Global Care Capital (CSE:HLTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Global Care Capital (CSE:HLTH)
Historical Stock Chart
From Jul 2023 to Jul 2024